Brief: Tenaya Therapeutics Doses First Patient In The Mypeak-1™ Phase 1B Clinical Trial Of TN-201 For The Treatment Of MYBPC3-Associated Hypertrophic Cardiomyopathy
05/10/2023 13:33
Oct 5 (Reuters) - Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS DOSES FIRST PATIENT IN THE MYPEAK-1™
PHASE
1B CLINICAL TRIAL OF TN-201 FOR THE TREATMENT OF
MYBPC3-ASSOCIATED HYPERTROPHIC CARDIOMYOPATHY
* TENAYA THERAPEUTICS INC - TENAYA ANTICIPATES SHARING
INITIAL
DATA FROM MYPEAK-1 TRIAL IN 2024
Source text for Eikon: ID:nGNX4w13dN
Further company coverage: TNYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027